Table 1.
Antimicrobial activity of telavancin tested against a worldwide collection of Gram-positive clinical isolates (2010)
| Organism/group and resistant subset (no. of isolates tested) | MIC (μg/ml) |
No. (cumulative %) of isolates inhibited at each telavancin MIC (μg/ml): |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 50% | 90% | ≤0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | |
| Staphylococcus aureus (7,653) | 0.12 | 0.25 | 1 (0.0) | 7 (0.1) | 232 (3.1) | 4,155 (57.4) | 2,962 (96.1) | 296 (100.0) | ||
| Oxacillin susceptible (4,565) | 0.12 | 0.25 | 0 (0.0) | 7 (0.2) | 172 (3.9) | 2,572 (60.3) | 1,660 (96.6) | 154 (100.0) | ||
| Oxacillin resistant (3,088) | 0.12 | 0.25 | 1 (0.0) | 0 (0.0) | 60 (2.0) | 1,583 (53.2) | 1,302 (95.4) | 142 (100.0) | ||
| Coagulase-negative staphylococci (1,278) | 0.12 | 0.25 | 6 (0.5) | 14 (1.6) | 88 (8.5) | 659 (60.0) | 473 (97.0) | 37 (99.9) | 1 (100.0) | |
| Oxacillin susceptible (332) | 0.12 | 0.25 | 0 (0.0) | 9 (2.7) | 36 (13.6) | 166 (63.6) | 115 (98.2) | 6 (100.0) | ||
| Oxacillin resistant (946) | 0.12 | 0.25 | 6 (0.6) | 5 (1.2) | 52 (6.7) | 493 (58.8) | 358 (96.6) | 31 (99.9) | 1 (100.0) | |
| Enterococcus faecalis (1,459)a | 0.5 | 0.5 | 0 (0.0) | 2 (0.1) | 8 (0.7) | 157 (11.4) | 461 (43.0) | 761 (95.2) | 38 (97.8) | 2 (97.9) |
| Vancomycin susceptible (1,421) | 0.5 | 0.5 | 0 (0.0) | 2 (0.1) | 8 (0.7) | 157 (11.8) | 460 (44.1) | 758 (97.5) | 36 (100.0) | |
| VanA type (32)a | >2 | >2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (6.3) |
| VanB type (6) | 0.5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 3 (66.7) | 2 (100.0) | ||
| Enterococcus faecium (805)b | 0.25 | >2 | 10 (1.2) | 86 (11.9) | 117 (26.5) | 164 (46.8) | 33 (50.9) | 11 (52.3) | 33 (56.4) | 156 (75.8) |
| Vancomycin susceptible (386) | 0.06 | 0.12 | 9 (2.3) | 82 (23.6) | 114 (53.1) | 152 (92.5) | 29 (100.0) | |||
| VanA type (392)b | 2 | >2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.3) | 9 (2.6) | 31 (10.5) | 156 (50.3) |
| VanB type (27) | 0.12 | 0.5 | 1 (3.7) | 4 (18.5) | 3 (29.6) | 12 (74.1) | 3 (85.2) | 2 (92.6) | 2 (100.0) | |
| Streptococcus pneumoniae (2,150) | ≤0.015 | 0.03 | 1,811 (84.2) | 329 (99.5) | 8 (99.9) | 2 (100.0) | ||||
| Penicillin susceptible (1,330) | ≤0.015 | 0.03 | 1,103 (82.9) | 222 (99.6) | 3 (99.8) | 2 (100.0) | ||||
| Penicillin nonsusceptible (820) | ≤0.015 | 0.03 | 708 (86.3) | 107 (99.4) | 5 (100.0) | |||||
| Beta-hemolytic streptococci (1,472) | 0.06 | 0.12 | 101 (6.9) | 564 (45.2) | 541 (81.9) | 263 (99.8) | 3 (100.0) | |||
| Group A (521) | 0.03 | 0.06 | 95 (18.2) | 346 (84.6) | 60 (96.2) | 20 (100.0) | ||||
| Group B (669) | 0.06 | 0.12 | 0 (0.0) | 51 (7.6) | 399 (67.3) | 216 (99.6) | 3 (100.0) | |||
| Group C (91) | 0.03 | 0.06 | 2 (2.2) | 54 (61.5) | 27 (91.2) | 8 (100.0) | ||||
| Group F (8) | 0.03 | 0 (0.0) | 6 (75.0) | 2 (100.0) | ||||||
| Group G (154) | 0.03 | 0.12 | 3 (1.9) | 87 (58.4) | 47 (89.0) | 17 (100.0) | ||||
| Viridans group streptococci (551) | 0.03 | 0.06 | 78 (14.2) | 333 (74.6) | 112 (94.9) | 28 (100.0) | ||||
| S. anginosus group (97) | 0.03 | 0.06 | 7 (7.2) | 68 (77.3) | 19 (96.9) | 3 (100.0) | ||||
| S. bovis group (32) | 0.03 | 0.06 | 4 (12.5) | 19 (71.9) | 6 (90.6) | 3 (100.0) | ||||
| Penicillin susceptible (416) | 0.03 | 0.06 | 66 (15.9) | 254 (76.9) | 80 (96.2) | 16 (100.0) | ||||
| Penicillin nonsusceptible (135) | 0.03 | 0.06 | 12 (8.9) | 79 (67.4) | 32 (91.1) | 12 (100.0) | ||||
a
A total of 30 VanA-type E. faecalis strains displayed telavancin MICs of >2 μg/ml.
b
A total of 195 VanA-type E. faecium strains displayed telavancin MICs of >2 μg/ml.